Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RORC | P51449 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5791086 | 1.00 | MAPT (0.52) | MAPTLMNAALDH1A1RORCSMN1; SMN2 | |
| SCHEMBL5764197 | 1.00 | MAPT (0.52) | MAPTLMNAALDH1A1RORCSMN1; SMN2 | |
| SCHEMBL5761621 | 0.87 | MAPT (0.43) | MAPTLMNAALDH1A1RORCSMN1; SMN2 | |
| SCHEMBL3368383 | 0.84 | RORC (0.51) | RORCGPR119NAMPTNR1H2 | |
| SCHEMBL3368376 | 0.84 | RORC (0.51) | RORCGPR119NAMPTNR1H2 | |
| SCHEMBL3368381 | 0.84 | RORC (0.51) | RORCGPR119NAMPTNR1H2 | |
| SCHEMBL5790189 | 0.83 | RORC (0.47) | RORCGPR119NAMPT | |
| SCHEMBL30833571 | 0.83 | RORC (0.47) | RORCGPR119NAMPT | |
| SCHEMBL5790185 | 0.83 | RORC (0.47) | RORCGPR119NAMPT | |
| SCHEMBL5763319 | 0.81 | PGR (0.36) | MAPTLMNAALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247286-A1 | Oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1656357-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005005399-A1 | OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247286-A1 | Oxazolidinone antibiotics and derivatives thereof | OXA1L, RORC, IL17A | MAPT 3563/4885LMNA 3911/4885ALDH1A1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.